LENZ Therapeutics (LENZ) Other Non-Current Assets (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Other Non-Current Assets of $2.5 million for Q1 2026, up 75.46% year-over-year from $1.4 million in Q1 2025, and down 3.46% quarter-over-quarter from $2.5 million in Q4 2025.
LENZ Therapeutics (LENZ) Other Non-Current Assets (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Other Non-Current Assets for 7 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 75.46% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 75.46% YoY), while the FY2025 annual figure was $2.5 million, up 81.76% from the prior year.
- Other Non-Current Assets slipped to $2.5 million in Q1 2026 per LENZ's latest filing, from $2.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.5 million in Q4 2025 and bottomed at $21000.0 in Q4 2023.
- Historically, Other Non-Current Assets has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 15500.0% — and 2024, when it slumped 98.78%.
- LENZ Therapeutics' Other Non-Current Assets stood at $1.3 million in 2022, then slumped by 98.37% to $21000.0 in 2023, then jumped by 6557.14% to $1.4 million in 2024, then soared by 81.76% to $2.5 million in 2025, then dropped by 3.46% to $2.5 million in 2026.
- Business Quant data shows LENZ's Other Non-Current Assets at $2.5 million in Q1 2026, $2.5 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Mn |
| Mar 31, 2026 | 2.45 Mn |
| Dec 31, 2025 | 2.54 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 1.72 Mn |
| Dec 31, 2022 | 1.29 Mn |
| Sep 30, 2022 | 844,000.00 |
| Jun 30, 2022 | 1.72 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 454,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 11,000.00 |